BACKGROUND: Patients with end-stage renal disease (ESRD) require dialysis to maintain survival. The optimal timing of dialysis initiation in terms of cost-effectiveness has not been established. METHODS: We developed a simulation model of individuals progressing towards ESRD and requiring dialysis. It can be used to analyze dialysis strategies and scenarios. It was embedded in an optimization frame worked to derive improved strategies. RESULTS: Actual (historical) and simulated survival curves and hospitalization rates were virtually indistinguishable. The model overestimated transplantation costs (10%) but it was related to confounding by Medicare coverage. To assess the model's robustness, we examined several dialysis strategies while input parameters were perturbed. Under all 38 scenarios, relative rankings remained unchanged. An improved policy for a hypothetical patient was derived using an optimization algorithm. CONCLUSION: The model produces reliable results and is robust. It enables the cost-effectiveness analysis of dialysis strategies.
BACKGROUND:Patients with end-stage renal disease (ESRD) require dialysis to maintain survival. The optimal timing of dialysis initiation in terms of cost-effectiveness has not been established. METHODS: We developed a simulation model of individuals progressing towards ESRD and requiring dialysis. It can be used to analyze dialysis strategies and scenarios. It was embedded in an optimization frame worked to derive improved strategies. RESULTS: Actual (historical) and simulated survival curves and hospitalization rates were virtually indistinguishable. The model overestimated transplantation costs (10%) but it was related to confounding by Medicare coverage. To assess the model's robustness, we examined several dialysis strategies while input parameters were perturbed. Under all 38 scenarios, relative rankings remained unchanged. An improved policy for a hypothetical patient was derived using an optimization algorithm. CONCLUSION: The model produces reliable results and is robust. It enables the cost-effectiveness analysis of dialysis strategies.
Authors: Joseph Menzin; Lisa M Lines; Daniel E Weiner; Peter J Neumann; Christine Nichols; Lauren Rodriguez; Irene Agodoa; Tracy Mayne Journal: Pharmacoeconomics Date: 2011-10 Impact factor: 4.981
Authors: Mohsen Yaghoubi; Sonya Cressman; Louisa Edwards; Steven Shechter; Mary M Doyle-Waters; Paul Keown; Ruth Sapir-Pichhadze; Stirling Bryan Journal: Appl Health Econ Health Policy Date: 2022-08-09 Impact factor: 3.686
Authors: Bernadette Li; John A Cairns; Heather Draper; Christopher Dudley; John L Forsythe; Rachel J Johnson; Wendy Metcalfe; Gabriel C Oniscu; Rommel Ravanan; Matthew L Robb; Paul Roderick; Charles R Tomson; Christopher J E Watson; J Andrew Bradley Journal: Value Health Date: 2017-05-12 Impact factor: 5.725
Authors: Wouter R Verberne; Janneke Dijkers; Johannes C Kelder; Anthonius B M Geers; Wilbert T Jellema; Hieronymus H Vincent; Johannes J M van Delden; Willem Jan W Bos Journal: BMC Nephrol Date: 2018-08-16 Impact factor: 2.388
Authors: Bjorg Thorsteinsdottir; Victor M Montori; Larry J Prokop; Mohammad Hassan Murad Journal: Clin Interv Aging Date: 2013-06-28 Impact factor: 4.458